Inhibition of IRAK-1 and IRAK-4, using pharmacological inhibitor or siRNA, sensitized melanoma tumors expressing phosphorylated forms of these IRAKs to cytotoxic chemotherapies in vivo, raising the possibility that IRAK family proteins may be potential therapeutic targets in cancer. This evidence concerns the gene IRAK1 and melanoma.